Table 2 Tumour characteristics of the included studies
Author | Specimen GS ≦ 7/˃ 7 | Staging system | T stage 1–2/3–4 | SM+/ SM− | No. of BCR (%) | Definition of BCR |
|---|---|---|---|---|---|---|
Wettstein et al. [35] | 292 /79 | WHO/ISUP 2016 | 263/108 | 133/238 | 49 (13.2%) | Rising and verified PSA levels > 0.1 ng/ml |
Xun et al. [6] | 131/41 | TNM 2002 | NA | 62/110 | 80 (46.5%) | The date of the first PSA elevated to 0.2 ng/ml |
Meyer et al. [36] | 879/24 | TNM 2002 | 903/0 | 37/206 | 137(15.2%) | PSA level of ≧ 0.2 ng/ml and rising after RP |
Gandaglia et al. [37] | 55/39 | TNM 2002 | 22/72 | 30/64 | 24 (25.5%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Shangguan et al. [33] | 131/41 | NA | NA | 62/110 | NA | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Zhang et al. [34] | 136/32 | TNM 2012 | NA | 30/138 | NA | First PSA elevated to 0.2 ng/ml |
Simon et al. [12] | 368/43 | NA | NA | 353/58 | 70 (17%) | Single PSA concentration of > 0.2, two concentrations at 0.2 ng/ml |
Sevcenco et al. [38] | 6645/560 | TNM 2009 | NA | 6137/1074 | 798 (11.1%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Pagano et al. [20] | 90/90 | TNM 2002 | NA | 74/106 | 120 (66.5%) | Two postoperative PSA values of ≧ 0.2 ng/ml |
Moschini et al. [39] | 647/364 | NA | 355/657 | 566/445 | 697 (69%) | PSA 0.4 ng/ml or greater |
Mortezavi et al. [40] | 86/14 | NA | 79/21 | 25/75 | 12 (12%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Mao et al. [41] | 78/28 | TNM 2002 | 63/43 | 20/86 | 31 (29.2%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Whalen et al. [29] | 516/93 | TNM 1997 | 435/174 | 483/126 | 73 (12%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Song et al. [42] | 1722/415 | NA | 1899/248 | 2132/13,433 | 466 (21.8%) | Greater than 0.2 ng/ml |
Reeves et al. [43] | 1306/142 | NA | 1042/454 | 390/1089 | 238 (20.5%) | Greater than 0.2 ng/ml |
Hashimoto et al. [5] | 634/373 | WHO 2004 | 677/160 | 243/594 | 102 (12.2%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Alvin et al. [44] | 663/58 | TNM 2010 | 497/228 | 311/414 | 104 (14%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Touijer et al. [13] | 184/185 | TNM 2010 | 46/323 | 138/231 | 201 (54%) | PSA ≧ 0.1 ng/ml with confirmatory rise |
Ritch et al. [45] | 783/196 | TNM 2002 | 955/24 | 335/644 | 317 (32.4%) | Greater than 0.2 ng/ml |
Kang et al. [21] | 2575/459 | TNM 2009 | NA | 974/2060 | NA | A serum PSA value of 0.4 ng/ml or greater after RP |
Fairey et al. [14] | 133/96 | TNM 2002 | 0/229 | 105/124 | 83 (36.2%) | Detectable PSA (ng/ml) followed by two consecutive confirmatory (1988–1994: PSA ≧ 0.3; 1995–2005: PSA ≧ 0.05; 2006–present: PSA ≧ 0.03) |
Turker et al. [46] | 167/164 | TNM 1994 | NA | 80/251 | 70 (21%) | Higher than 0.2 ng/ml on 2 separate measurements 1 month apart |
Sammon et al. [10] | 760/34 | AJCC 2002 | 592/202 | 162/632 | 107 (13.5%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Chen et al. [30] | 109/43 | NA | 0/152 | 27/125 | 80 (52.6%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Sooriakumaran et al. [11] | 900/44 | NA | 651/230 | 194/704 | 135 (15.2%) | Greater than 0.2 ng/ml |
Lu et al. [31] | 796/98 | TNM 2010 | 703/191 | 250/644 | 277 (31%) | PSA ≧ 0.1 ng/ml with confirmatory rise |
Iremashvili et al. [47] | 1286/258 | NA | NA | 479/965 | 210 (15%) | Greater than 0.2 ng/ml |
Connolly et al. [48] | 95/65 | NA | 65/95 | 60/100 | 88 (55%) | Greater than 0.2 ng/ml |
Busch et al. [49] | 1538/307 | NA | 1802/9 | 537/1308 | 450 (24.4%) | PSA ≧ 0.1 ng/ml with confirmatory rise |
Berge et al. [50] | 553/24 | TNM 2002 | 441/136 | 168/409 | 91 (16%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Lee et al. [51] | 236/764 | NA | NA | 337/663 | 99 (9.9%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Alenda et al. [23] | 1248/0 | NA | NA | 400/843 | 176 (16.9%) | PSA > 0.2 ng/mL |
Fukuhara et al. [52] | 332/32 | TNM 2002 | 275/89 | 157/207 | 66 (18.1%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Cho et al. [53] | 153/14 | TNM 2002 | 126/45 | 58/109 | 15 (8.8%) | A serum PSA value of 0.4 ng/ml or greater after RP |
Alkhateeb et al. [26] | 1159/109 | NA | 853/415 | 264/1004 | NA | A serum PSA value of 0.4 ng/ml or greater after RP |
Jeon et al. [54] | 190/45 | TNM 2002 | 145/92 | 86/151 | 67 (28.3%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Schroeck et al. [55] | 2855/359 | NA | 1991/1166 | 982/2212 | 706 (25.7%) | Greater than 0.2 ng/ml |
Pavlovich et al. [56] | 494/14 | TNM 2002 | 416/92 | 69/439 | 102 (20%) | Two consecutive increases in PSA ≧ 0.2 ng/ml |
Hong et al. [57] | 361/11 | TNM 2002 | 371/0 | 46/326 | NA | First value greater than 0.2 ng/ml |
Cheng et al. [8] | 410/94 | TNM 1997 | 348/156 | 174/330 | 157 (21.2%) | Two consecutive increases in PSA ≧ 0.1 ng/ml |
Shariat et al. [58] | 565/65 | TNM 1997 | NA | 179/451 | 80 (12.7%) | First value greater than 0.2 ng/ml |